It is especially important to be able to monitor use of GnRH agonists in men with prostate cancer given limited evidence of efficacy, particularly in men with substantial comorbidity, and the increasing recognition of life threatening adverse effects such as bone fracture and cardiovascular disease [11,12,24-27]. This evidence concerns the gene GNRH1 and cardiovascular disorder.